**GoodRx Holdings Reports Fiscal Year 2025 Results**

GoodRx Holdings, Inc. (GDRX) announced its financial results for the fiscal year ended December 31, 2025, reporting a total revenue of $796.9 million, a 1% increase compared to $792.3 million in 2024. The company's net income for the year was $30.4 million, resulting in a net income margin of 3.8%, a notable increase from the $16.4 million net income and 2.1% margin reported in the previous fiscal year. Adjusted EBITDA, a non-GAAP measure, reached $270.5 million, with an Adjusted EBITDA Margin of 33.9%, compared to $260.2 million and 32.8% in 2024, respectively.

The company experienced shifts in revenue composition across its key offerings. Prescription transactions revenue, which constitutes a significant portion of GoodRx's business, decreased by 6% to $544.0 million, down from $577.5 million in the prior year. Subscription revenue also saw a slight decline of 3%, amounting to $83.8 million compared to $86.5 million in 2024. However, pharma direct revenue demonstrated substantial growth, increasing by 41% to $151.4 million, up from $107.2 million in the previous year, driven by organic growth as the company continued to expand its market penetration with pharma manufacturers and other customers.

Key operational metrics also reflected these changes. Monthly Active Consumers (MACs) averaged 5.3 million for the three months ended December 31, 2025, a decrease from 6.6 million for the same period in 2024. Subscription plans totaled 674,000 as of December 31, 2025, a slight decrease from 684,000 at the end of 2024. The company attributed the decline in prescription transactions revenue and MACs to broader changes in the retail pharmacy landscape, including store closures and volume reduction in one of its integrated savings programs.

Looking ahead, GoodRx anticipates that pharma direct revenue will continue to grow as a percentage of total revenue in the near to medium term. The company is focused on delivering consistent and efficient growth by reprioritizing investments to where they are most needed while delivering to consumers what they have come to expect from GoodRx. The company also noted the potential impact of new government initiatives, such as "TrumpRx.gov," on its business, although the specific effects remain unclear at this time.

About GoodRx Holdings, Inc.

GoodRx Holdings, Inc. operates a digital healthcare platform providing price transparency and savings solutions for prescription medications in the U.S. It offers price comparison tools, subscription plans, telehealth services, and pharma manufacturer solutions, serving consumers, healthcare providers, pharmacies, PBMs, and pharma companies. The company's value lies in improving medication affordability, adherence, and access through proprietary technology, industry partnerships, and data-driven insights.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.